Endothelin and Gelatinases in Renal Changes Following Blockade of Nitric Oxide Synthase in Hypertensive Rats

Yi-Ling Yang；Demeral David Liu；Nan-Kuang Hsieh；Hsing I Chen

glomerular sclerosis ； arteriosclerosis ； nitric oxide ； matrix metalloproteinases ； endothelin

The Chinese Journal of Physiology

51卷3期（2008 / 06 / 30）

186 - 195

英文

We investigated the involvement of matrix metalloproteinases (MMPs), tissue inhibitor (TIMP) and endothelin-1 (ET-1) in the renal damage in spontaneously hypertensive rats (SHR) following nitric oxide (NO) deprivation. SHR received N(superscript ω)-nitro-L-arginine methyl ester (L-NAME) from 5 wk-old for a period of 30 days. An ET(subscript A) antagonist, FR139317 was used. We gave SHR FR139317 alone and cotreatment with L-NAME. L-NAME caused systemic hypertension, decrease in plasma nitrate/nitrite, increases in blood urea nitrogen and creatinine, impairment of glomerular dynamics. NO deprivation reduced the renal tissue cGMP, but it increased the collagen volume fraction, number of sclerotic glomeruli, arteriolar injury score and glomerular injury score. In addition, L-NAME elevated the plasma ET-1 at day 5. Cotreatment with FR139317 alleviated the L-NAME-induced functional and structural changes of renal glomeruli. L-NAME administration for 5 to 10 days resulted in decreases in MMP2 and MMP9 with increasing TIMP2. After L-NAME for 15 days, opposite changes (increases in MMP2 and MMP9 with a decrease in TIMP2) were observed. FR139317 cotreatment ameliorated the L-NAME-induced changes in MMP2 and MMP9 throughout the 30-day observation period. The ET(subscript A) antagonist cotreatment attenuated the L-NAME-induced increase in TIMP2 before day 15, but not after day 20. The results indicate that ET-1, MMPs and TIMP are involved at the early stage (before 10 days) of glomerular sclerosis and arteriosclerosis with functional impairment following NO deprivation. The changes in MMPs and TIMP at the late stage (after 20 days) may be a compensatory response to prevent further renal damage.

1. Chen, H.I.,Chang, H.R.,Wu, C.Y.,Kao, S.J.,Wang, D.,Hsieh, N. K.,Hsu, Y.H.(2007).Nitric oxide in the cardiovascular and pulmonary circulation-a brief review of literatures and historical landmarks.Chinese J. Physiol.,50,43-50.
   連結：
2. Hsu, Y.H.,Hsu, B.G.,Chen, H.I.(2007).Malignant alterations following early blockade of nitric oxide synthase in hypertensive rats.Chinese J. Physiol.,50,1-11.
   連結：
3. Ammarguellat, F.Z.,Gannon, P.O.,Amiri, F.,Schiffrin, E.L.(2002).Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors.Hypertension,39,679-684.
4. Benjamin, N.,Vane, J.(1996).Nitric oxide and hypertension.Circulation,94,1197-1198.
5. Boffa, J.J.,Tharaux, P.L.,Dussaule, J.C.,Chatziantoniou, C.(2001).Regression of renal vascular fibrosis by endothelin receptor antagonism.Hypertension,37,490-496.
6. Camp, T.M.,Smiley, L.M.,Hayden, M.R.,Tyagi, S.C.(2003).Mechanism of matrix accumulation and glomerulosclerosis in spontaneously hypertensive rats.J. Hypertens.,21,1719-1727.
7. Catania, J.M.,Chen, G.,Parrish, A.R.(2007).Role of matrix metalloproteinases in renal pathophysiologies.Am. J. Physiol. Renal Physiol.,292,905-911.
8. Chen, H.I.,Hu, C.T.(1997).Endogenous nitric oxide on arterial hemodynamics: a comparison between normotensive and hypertensive rats.Am. J. Physiol.,273,1816-1823.
9. Donnelly, R.,Collinson, D.J.,Manning, G.(2003).Hypertension, matrix metalloproteinases and target organ damage.J. Hypertens.,21,1627-1630.
10. Eberhardt, W.,Beeg, T.,Beck, K.F.,Walpen, S.,Gauer, S.,Bohles, H.,Pfeilschifter, J.(2000).Nitric oxide modulates expression of matrix metalloproteinase-9 in rat mesangial cells.Kidney Int.,57,59-69.
11. Elijovich, F.,Laffer, C.L.,Amador, E.,Gavras, H.,Bresnahan, M. R.,Schiffrin, E.L.(2001).Regulation of plasma endothelin by salt in salt-sensitive hypertension.Circulation,103,263-268.
12. Ergul, A.,Portik-Dobos, V.,Giulumian, A.D.,Molero, M.M.,Fuchs, L.C.(2003).Stress upregulates arterial matrix metalloproteinase expression and activity via endothelin A receptor activation.Am. J. Physiol. Heart Circ. Physiol.,285,2225-2232.
13. Fernandez-Patron, C.,Radomski, M.W.,Davidge, S.T.(1999).Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor.Circ. Res.,85,906-911.
14. Fernandez-Patron, C.,Zouki, C.,Whittal, R.,Chan, J.S.,Davidge, S.T.,Filep, J.G.(2001).Matrix metalloproteinases regulate neutrophilendothelial cell adhesion through generation of endothelin-1[1-32].FASEB J.,15,2230-2240.
15. Fischer, P.A.,Dominguez, G.N.,Cuniberti, L.A.,Martinez, V.,Werba, J.P.,Ramirez, A.J.,Masnatta, L.D.(2003).Hyperhomocysteinemia induces renal hemodynamic dysfunction: is nitric oxide involved?.J. Am. Soc. Nephrol.,14,653-660.
16. Gurjar, M.V.,Sharma, R.V.,Bhalla, R.C.(1999).eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity.Arterioscler. Thromb. Vasc. Biol.,19,2871-2877.
17. Harrison, D.G.(1997).Cellular and molecular mechanisms of endothelial cell dysfunction.J. Clin. Invest.,100,2153-2157.
18. Hsieh, N.K.,Wang, J.Y.,Liu, J.C.,Lee, W.H.,Chen, H.I.(2004).Structural changes in cerebral arteries following nitric oxide deprivation: a comparison between normotensive and hypertensive rats.Thromb. Haemost.,92,162-170.
19. Hu, C.T.,Chang, H.R.,Hsu, Y.H.,Liu, C.J.,Chen, H.I.(2005).Ventricular hypertrophy and arterial hemodynamics following deprivation of nitric oxide in rats.Life Sci.,78,164-173.
20. Hu, C.T.,Chang, K.C.,Wu, C.Y,Chen, H.I.(1997).Acute effects of nitric oxide blockade with L-NAME on arterial haemodynamics in the rat.Br. J. Pharmacol.,122,1237-1243.
21. Iglarz, M.,Touyz, R.M.,Amiri, F.,Lavoie, M.F.,Diep, Q.N.,Schiffrin, E.L.(2003).Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelindependent hypertension.Arterioscler. Thromb. Vasc. Biol.,23,45-51.
22. Jeyabalan, A.,Novak, J.,Danielson, L.A.,Kerchner, L.J.,Opett, S. L.,Conrad, K.P.(2003).Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries.Circ. Res.,93,1249-1257.
23. Kolpakov, V.,Gordon, D.,Kulik, T.J.(1995).Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells.Circ. Res.,76,305-309.
24. Koyanagi, M.,Egashira, K.,Kitamoto, S.,Ni, W.,Shimokawa, H.,Takeya, M.,Yoshimura, T.,Takeshita, A.(2000).Role of monocyte chemoattractant protein-1 in cardiovascular remodeling induced by chronic blockade of nitric oxide synthesis.Circulation,102,2243-2248.
25. Laviades, C.,Varo, N.,Fernandez, J.,Mayor, G.,Gil, M.J.,Monreal, I.,Diez, J.(1998).Abnormalities of the extracellular degradation of collagen type I in essential hypertension.Circulation,98,535-540.
26. Lee, R.P.,Wang, D.,Lin, N.T.,Chen, H.I.(2002).Physiological and chemical indicators for early and late stages of sepsis in conscious rats.J. Biomed. Sci.,9,613-621.
27. Levin, E.R.(1995).Endothelins.N. Engl. J. Med.,333,356-363.
28. Li, L.,Fink, G.D.,Watts, S.W.,Northcott, C.A.,Galligan, J.J.,Pagano, P.J.,Chen, A.F.(2003).Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in lowrenin hypertension.Circulation,107,1053-1058.
29. Li-Saw-Hee, F.L.,Edmunds, E.,Blann, A.D.,Beevers, D.G.,Lip, G.Y.(2000).Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy.Int. J. Cardiol.,75,43-47.
30. Mai, M.,Geiger, H.,Hilgers, K.F.,Veelken, R.,Mann, J.F.,Dammrich, J.,Luft, F.C.(1993).Early interstitial changes in hypertension-induced renal injury.Hypertension,22,754-765.
31. Matsui, K.,Takano, Y.,Yu, Z.X.,Hi, J.E.,Stetler-Stevenson, W.G.,Travis, W.D.,Ferrans, V.J.(2002).Immunohistochemical study of endothelin-1 and matrix metalloproteinases in plexogenic pulmonary arteriopathy.Pathol. Res. Pract.,198,403-412.
32. Matsumura, Y.,Kuro, T.,Kobayashi, Y.,Konishi, F.,Takaoka, M.,Wessale, J.L.,Opgenorth, T.J.,Gariepy, C.E.,Yanagisawa, M.(2000).Exaggerated vascular and renal pathology in endothelin-B receptor-deficient rats with deoxycorticosterone acetate-salt hypertension.Circulation,102,2765-2773.
33. Ono, H.,Ono, Y.,Frohlich, E.D.(1995).Nitric oxide synthase inhibition in spontaneously hypertensive rats. Systemic, renal, and glomerular hemodynamics.Hypertension,26,249-255.
34. Parks, W.C.,Meccham, R.P. (eds.)(1998).Matrix Metalloproteinases.San Diego, Calif.:Academic Press.
35. Pollanen, P.J.,Karhunen, P.J.,Mikkelsson, J.,Laippala, P.,Perola, M.,Penttila, A.,Mattila, K.M.,Koivula, T.,Lehtimaki, T.(2001).Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study.Arterioscler. Thromb. Vasc. Biol.,21,1446-1450.
36. Raij, L.(1998).Nitric oxide in hypertension: relationship with renal injury and left ventricular hypertrophy.Hypertension,31,189-193.
37. Rothermund, L.,Vetter, R.,Dieterich, M.,Kossmehl, P.,Gogebakan, O.,Yagil, C.,Yagil, Y.,Kreutz, R.(2002).Endothelin-A receptor blockade prevents left ventricular hypertrophy and dysfunction in salt-sensitive experimental hypertension.Circulation,106,2305-2308.
38. Schiffrin, E.L.(2000).Endothelin: Role in experimental hypertension.J. Cardiovasc. Pharmacol.,35,33-35.
39. Tharaux, P.L.,Chatziantoniou, C.,Casellas, D.,Fouassier, L.,Ardaillou, R.,Dussaule, J.C.(1999).Vascular endothelin-1 gene expression and synthesis and effect on renal type I collagen synthesis and nephroangiosclerosis during nitric oxide synthase inhibition in rats.Circulation,99,2185-2191.
40. Tsuruda, T.,Costello-Boerrigter, L.C.,Burnett, J.C.(2004).Matrix metalloproteinases: pathways of induction by bioactive molecules.Heart Fail. Rev.,9,53-61.
41. Visse, R.,Nagase, H.(2003).Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry.Circ. Res.,92,827-839.
42. Yao, J.,Morioka, T.,Li, B.,Oite, T.(2001).Endothelin is a potent inhibitor of matrix metalloproteinase-2 secretion and activation in rat mesangial cells.Am. J. Physiol. Renal Physiol.,280,628-635.
43. Yasmin, McEniery, C.M.,Wallace, S.,Dakham, Z.,Pulsalkar, P.,Maki-Petaja, K.,Ashby, M.J.,Cockcroft, J.R.,Wilkinson, I.B.(2005).Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness.Arterioscler. Thromb. Vasc. Biol.,25,372-378.
44. Yu, H.C.,Burrell, L.M.,Black, M.J.,Wu, L.L.,Dilley, R.J.,Cooper, M.E.,Johnston, C.I.(1998).Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats.Circulation,98,2621-2628.
45. Zatz, R.,Baylis, C.(1998).Chronic nitric oxide inhibition model six years on.Hypertension,32,958-964.
46. Zeidan, A.,Broman, J.,Hellstrand, P.,Sward, K.(2003).Cholesterol dependence of vascular ERK1/2 activation and growth in response to stretch: role of endothelin-1.Arterioscler. Thromb. Vasc. Biol.,23,1528-1534.
47. Zervoudaki, A.,Economou, E.,Pitsavos, C.,Vasiliadou, K.,Aggeli, C.,Tsioufis, K.,Toutouza, M.,Stefanadis, C.,Toutouzas, P.(2004).The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and-9 in essential hypertension.Am. J. Hypertens.,17,273-276.
48. Zhao, Q.,Egashira, K.,Inoue, S.,Usui, M.,Kitamoto, S.,Ni, W.,Ishibashi, M.,Hiasa, Ki K.,Ichiki, T.,Shibuya, M.,Takeshita, A.(2002).Vascular endothelial growth factor is necessary in the development of arteriosclerosis by recruiting/activating monocytes in a rat model of long-term inhibition of nitric oxide synthesis.Circulation,105,1110-1115.